Ken Griffin Athira Pharma, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.42 - $3.43 $840 - $6,860	2,000 Added 9.26%	23,600 $10,000
Q2 2024 Aug 14, 2024	BUY	$1.92 - $2.71 $24,576 - $34,688	12,800 Added 145.45%	21,600 $57,000
Q1 2024 May 15, 2024	SELL	$2.24 - $4.15 $542,752 - $1.01 Million	-242,300 Reduced 96.5%	8,800 $24,000
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.46 $4,587 - $8,118	-3,300 Reduced 1.3%	251,100 $610,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $9,880 - $16,432	-5,200 Reduced 2.0%	254,400 $513,000
Q2 2023 Aug 14, 2023	BUY	$2.36 - $3.59 $17,228 - $26,207	7,300 Added 2.89%	259,600 $765,000
Q1 2023 May 15, 2023	SELL	$2.26 - $4.22 $355,271 - $663,384	-157,200 Reduced 38.39%	252,300 $630,000
Q4 2022 Feb 14, 2023	SELL	$2.76 - $3.71 $25,943 - $34,874	-9,400 Reduced 2.24%	409,500 $1.3 Million
Q3 2022 Nov 14, 2022	SELL	$2.93 - $3.96 $918,262 - $1.24 Million	-313,400 Reduced 42.8%	418,900 $1.24 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.